Prognostic factors for successful induction of labor in intrauterine growth restriction after 36 weeks of gestation.


Journal

European journal of obstetrics, gynecology, and reproductive biology
ISSN: 1872-7654
Titre abrégé: Eur J Obstet Gynecol Reprod Biol
Pays: Ireland
ID NLM: 0375672

Informations de publication

Date de publication:
Sep 2022
Historique:
received: 28 05 2022
revised: 24 07 2022
accepted: 29 07 2022
pubmed: 9 8 2022
medline: 1 9 2022
entrez: 8 8 2022
Statut: ppublish

Résumé

In comparison to eutrophic fetuses, intra uterine growth restriction fetuses (IUGR) have a higher risk of perinatal morbi-mortality. There are no guidelines on the labor induction of labor (IOL) method to be performed in IUGR. The main objective was to determine fetal and maternal predictive factors of successful induction in IUGR fetuses from 36 weeks. Study design We conducted a retrospective cohort single-center study including 320 women with a cephalic fetal presentation. Labour was induced after 36 weeks for suspected IUGR between January 2013 and December 2019. Among the 320 patients, 246 were delivered vaginally (76.9 %) and 74 had a cesarean (23.1 %). Prognostic factors for successful IUGR induction were nonscarring uterus (OR 8.41; 95 %CI [2.92-24.21]), absence of preeclampsia (OR 7.14; 95 %CI [2.42-21.03]), multiparity (OR 4.32; 95 %CI [1.83-10.18]), normal fetal heart rate before IOL (OR 2.99; 95 %CI [1.24-7.22]) and BMI < 30 (OR 3.54; 95 %CI [1.62-7.72]). Doppler abnormalities, method and number of line of IOL, cervical evaluation were not significant in our study. The prognostic factors for successful IUGR induction are essentially maternal. Thus, a low BMI, multiparity, nonscarring uterus, absence of preeclampsia, and a normal FHR are good prognostic factors in IUGR induction.

Identifiants

pubmed: 35939909
pii: S0301-2115(22)00455-9
doi: 10.1016/j.ejogrb.2022.07.032
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

213-218

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Manon Metrop (M)

CHU Lille, Department of Obstetrics, F-59000 Lille, France.

Florence Leblanc (F)

CHU Lille, Department of Obstetrics, F-59000 Lille, France.

Emeline Cailliau (E)

Department of Biostatistics, CHRU Lille, France.

Damien Subtil (D)

CHU Lille, Department of Obstetrics, F-59000 Lille, France; Univ. Lille, CHU Lille, ULR 2694 - METRICS - Evaluation des technologies de santé et des pratiques médicales, F-59000 Lille, France.

Veronique Houfflin-Debarge (V)

CHU Lille, Department of Obstetrics, F-59000 Lille, France; Univ. Lille, CHU Lille, ULR 2694 - METRICS - Evaluation des technologies de santé et des pratiques médicales, F-59000 Lille, France.

Charles Garabedian (C)

CHU Lille, Department of Obstetrics, F-59000 Lille, France; Univ. Lille, CHU Lille, ULR 2694 - METRICS - Evaluation des technologies de santé et des pratiques médicales, F-59000 Lille, France.

Louise Ghesquière (L)

CHU Lille, Department of Obstetrics, F-59000 Lille, France; Univ. Lille, CHU Lille, ULR 2694 - METRICS - Evaluation des technologies de santé et des pratiques médicales, F-59000 Lille, France. Electronic address: louise.ghesquiere@chu-lille.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH